Work Here?
About Shape Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$147.5M
Headquarters
Seattle, Washington
Founded
2018
Overview
Shape Therapeutics focuses on programmable RNA medicine, utilizing artificial intelligence to analyze extensive datasets for developing new treatments. Their primary product involves designing novel RNAs that can reprogram cells to address diseases by correcting mutations and adjusting gene expression. A standout feature of their technology is RNAfix, which employs a natural enzyme to modify RNA instructions without altering DNA, allowing for the correction of genetic disorders. Additionally, ShapeTX employs smart-sensing vector designs to customize gene expression for specific cell types, enhancing treatment options beyond traditional methods. The company distinguishes itself from competitors by integrating AI with RNA technology to create medicines that are not only effective and safe but also easy to manufacture. The ultimate goal of Shape Therapeutics is to unlock the therapeutic potential of RNA to tackle the root causes of various diseases.
Simplify's Take
What believers are saying
- Increased interest in RNA therapies boosts ShapeTX's market potential.
- AI integration in drug discovery enhances ShapeTX's innovative capabilities.
- FDA fast-tracking of RNA therapies supports ShapeTX's regulatory pathway.
What critics are saying
- Intellectual property disputes may arise in the competitive RNA therapy field.
- Regulatory challenges due to rapid AI and RNA advancements could impact ShapeTX.
- Talent war in biotech may lead to recruitment challenges for ShapeTX.
What makes Shape Therapeutics unique
- ShapeTX uses AI to design novel RNAs for precise gene therapy.
- Their RNAfix technology corrects RNA without altering DNA, offering unique therapeutic potential.
- Smart-sensing vector designs enable tailored gene expression, surpassing first-generation gene therapies.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$147.5M
Above
Industry Average
Funded Over
2 Rounds
New Enterprise AssociatesIndustry standards
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Paid Holidays
Parental Leave
Unlimited Paid Time Off
Disability Insurance
401(k) Retirement Plan
Life Insurance
Health Savings Account/Flexible Spending Account
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 10%2 year growth
↑ 12%Shape Therapeutics, a leader in RNA-based gene therapy, today released two preprint manuscripts detailing major technological breakthroughs that underpin the company's therapeutic editing platform RNAfix(R).
SEATTLE, June 25, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics, Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, announces the appointments of David Epstein, former CEO of Seagen, and Todd Simpson, former CFO of Seagen, to its board of directors. “We are at a pivotal moment where our investment in breakthrough technologies is now yielding industry-leading results. As we prepare to advance our RNA editing therapies to the clinic, we are thrilled to welcome David and Todd to our board," said Francois Vigneault, Ph.D., chief executive officer of ShapeTX. "Their expertise in scaling life sciences companies, from drug development to clinical success and commercialization, will be invaluable.” David Epstein is a highly respected leader in the pharmaceutical and biotech sectors, renowned for steering Seagen towards a pivotal $44.5 billion acquisition by Pfizer. With over 30 years of global experience in drug development, commercialization, and leadership, David has previously served as an executive partner at Flagship Pioneering and as CEO of Novartis Pharmaceuticals, including its Oncology and Molecular Diagnostic units, transforming it into the second-largest oncology division globally
SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- Shape Therapeutics Inc. (ShapeTX), a leader at the convergence of AI and RNA editing to revolutionize genomic medicine, is pleased to announce the appointment of Matt Valentino as Chief People Officer.Before joining ShapeTX, Matt was at the helm of diverse People teams for notable biotech and technology companies including Calico Labs, Genentech, Pandora, Validant, and DoorDash.“Matt brings extensive experience in leading teams at scientific R&D companies focused on drug development, manufacturing, robotics, and AI/ML applications. As an early team member at Calico Labs, he played a crucial role in scaling the company from 70 to over 300 employees, including the expansion of their Drug Discovery, Computational and Clinical Development teams. While at DoorDash, Matt facilitated growth from 2,000 to over 17,000 global employees. His expertise will be instrumental in guiding ShapeTX through its next growth phase as we continue to innovate at the intersection of technology and biotechnology," said Francois Vigneault, Ph.D., Co-Founder and CEO of ShapeTX. "We are confident in Matt's leadership and excited about the future developments he will drive at ShapeTX." Matt added, "I’m thrilled to join the talented team at ShapeTX, and I am eager to advance our mission of repairing genetic causes of disease with programmable RNA medicines."About ShapeTXShape Therapeutics operates at the convergence of AI and RNA editing to revolutionize genomic medicine
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases.
Otsuka collaborates with ShapeTX to develop novel AAV gene therapies for ocular diseases.
There are no jobs for Shape Therapeutics right now.
Find jobs on Simplify and start your career today
About Shape Therapeutics
Industries
AI & Machine Learning
Biotechnology
Company Size
51-200
Company Stage
Series B
Total Funding
$147.5M
Headquarters
Seattle, Washington
Founded
2018
There are no jobs for Shape Therapeutics right now.
Find jobs on Simplify and start your career today